AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

by Ysios Capital

AELIX Therapeutics, a biopharmaceutical company backed by Ysios Capital based in Barcelona, Spain, that focuses on HIV vaccine development, today announced that Gilead Sciences, Inc. (Nasdaq: GILD), b...

Read more

RCD asesora a Aelix Therapeutics en la ronda de financiación de 11,5 millones de euros que se destinarán al desarrollo de una vacuna contra el sida

by RCD

RCD cuenta con amplia experiencia y conocimiento en el asesoramiento a instituciones públicas de investigación y a compañías biotecnológicas, a las que presta un servicio integral en aspectos com...

Read more

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Addleshaw Goddard delivers 17% headline ...

by Addleshaw Goddard

Addleshaw Goddard (AG), the London-headquartered international law fir...

Photos Stream